Editorial
D
ual antiplatelet therapy (DAPT), the combination of aspirin and an inhibitor of the platelet P2Y 12 receptor, is the foundation to prevent acute stent thrombosis (ST), the sudden thrombotic coronary occlusion that can lead to myocardial infarction or death in one third of patients. 1 The appropriate duration of DAPT in patients who have received coronary stents is an important dilemma for interventional cardiologists and a daily concern. We have entered the third decade of coronary stent implantation, the dominant strategy for myocardial revascularization, without clear guidance on the duration of DAPT. 2 Professional guidelines are not entirely consistent, recommending extension of DAPT up to 6 months after implantation of a second-generation drug-eluting stent (DES) 3 or at least 12 months after implantation of a DES unless patients are at high risk for bleeding. 4 None of these guidelines recommend long-term or lifelong DAPT. The current discrepancies may reflect either a different interpretation of the data by experts of the guideline committees or, more likely, an active area of clinical investigation in which early certainties about DAPT duration after coronary stenting are being challenged.
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So far, 12 randomized, interruption studies investigating various durations of DAPT, whether short, intermediate, or prolonged (≥2 years), have been conducted (Figure) . All published randomized trials to date (n>19 000) indicate no benefit of extended DAPT with clopidogrel beyond 6 or 12 months after DES but harm, 5 suggesting that the pendulum has swung back toward short DAPT duration (Table) . The lack of power for important safety end points such as death, major bleeding, or ST is a common limitation of these trials. In addition, 1 randomized trial 6 and 2 registries 7, 8 suggest that DAPT duration should be device specific, further adding complexity to this unresolved issue. Finally, most of the evidence has been obtained with clopidogrel, whereas more potent P2Y 12 inhibitors such as ticagrelor and prasugrel have demonstrated superiority over clopidogrel in reducing spontaneous myocardial infarction and ST after stenting.
Long-term DAPT of 6 to 12 months has been recommended 9 to overcome the susceptibility of first-generation DES to ST, accounted for mainly by delayed endothelialization and polymer hypersensitivity. 10 There was no randomized evidence to support this endorsement for the approved devices. The 2014 European myocardial revascularization guidelines recommend 6 months of DAPT after implantation of a new-generation DES on the basis of randomized trials demonstrating enhanced safety and effectiveness with these devices compared with their earlier counterparts. 2 An even shorter duration may be used when there is a high risk of bleeding. These guidelines refer only to new-generation DES. The same guidelines also specify that DAPT may be used beyond 6 months in patients at high ischemic risk and low bleeding risk, further recognizing that prolonged DAPT may be useful and that optimal duration for DAPT is difficult to appraise.
Avoidance of spontaneous myocardial infarction is a clear advantage of prolonged DAPT as demonstrated with clopidogrel versus placebo 11 and more recently with prasugrel versus clopidogrel when coronary artery disease is characterized angiographically. 11, 12 In the prespecified angiographic substudy of the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY-ACS) substudy, treatment effect diverged significantly after 12 months in favor of prasugrel without a significant excess of major bleeding in this medically managed non--ST-segment--elevation acute coronary syndrome population. Reaching the optimal net clinical benefit by fine-tuning the potency and duration of DAPT is a key step to further improve outcomes after DES. This was the main goal of the TAXUS Liberté Post-Approval Study (TL-PAS), a surveillance of DES performance after commercial release to fulfill a US Food and Drug Administration requirement. The primary objective of this observational registry was to collect safety
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and clinical outcomes data for the first 12 months after implantation of ≥1 TAXUS Liberté stents with prasugrel as the thienopyridine component of DAPT; then patients who had no contraindication to prolonged DAPT could be randomized to receive in a double-blind fashion prolonged DAPT or single aspirin therapy. This second part of the study, published in this issue of Circulation, 13 was also included in the randomized, double-blind DAPT Trial, which has been published in the New England Journal of Medicine. 14 The results of both studies were also recently presented and discussed at the American Heart Association Scientific Sessions.
In the present study by Garratt et al, 13 a newer version of the paclitaxel-eluting stent was evaluated with a thinner-strut stainless steel novel cell design (97-μm struts) with a more conformable platform embedded with a durable polymer (Boston Scientific, Natick, MA). This evaluation of the TAXUS Liberté stent beyond 12 months after implantation included in the randomized, double-blind DAPT Trial represents a subset of this large trial and can be interpreted only according to the main results of the DAPT Trial. Although, the present study is an exploratory analysis without initial power calculation and is not powered for the DAPT study end points, the results are globally similar, with the main findings of the larger overall DAPT Trial of all stent types and P2Y12 inhibitors suggesting that the information is not only plausible but certainly real. The first insight is that DAPT beyond 1 year reduces ischemic events in low-risk patients who received a stent at high risk of ST without significant harm. Second, this is the first long-term assessment of an off-label use of prasugrel in patients who were not all acute coronary syndrome patients and were implanted with a first-generation DES. Third, the extended follow-up 3 months after interruption provides additional information in line with prior studies showing a rebound of platelet reactivity and clinical events that suggest a causal relationship between the two; this finding appears to justify long-term, if not lifelong, treatment in these patients who received a paclitaxel stent. 15 Fourth, the TL-PAS outlines that, besides patient characteristics and clinical setting (stable versus unstable presentation), the type of stent drives also clinical outcome. Finally, randomization at 12 months selected patients free of events and drug compliant. Not all eligible patients were randomized, reflecting the reallife management of antiplatelet therapy. 5 The authors should be commended for the low rate of premature study interruption.
The unusual high event rates in the study provide additional evidence that paclitaxel-eluting stents, even after refinement of the platform design, are associated with an excess risk of ST and major adverse cardiac events. These stents are a concern in terms of safety, which may be somewhat handled by long-term use of prasugrel. This is a call for no longer using first-generation DES, paclitaxel-eluting stents in particular. This is also 1 more piece of information pushing to a reappraisal of landmark studies that used paclitaxel stents exclusively such as the Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) study. 16 The main point of interest of TL-PAS is its incorporation into the DAPT randomized study, confirming a favorable risk-to-benefit ratio with a longer duration of P2Y 12 receptor inhibitor therapy after stent implantation.
14 Whether longer and stronger DAPT better applies to paclitaxel-eluting stents, to the first generation of DES, or to any DES is not clear yet. Nevertheless, there is a new shift in paradigm for antiplatelet therapy-based secondary prevention. TL-PAS is a nice illustration that drugs and stents interact closely and help each other.
